Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
VivoSim Labs, Inc. - Common Stock
(NQ:
VIVS
)
0.2394
+0.1194 (+99.50%)
Delayed Quote
Updated: 12:45 PM EST, Nov 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about VivoSim Labs, Inc. - Common Stock
< Previous
1
2
Next >
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
Today 8:05 EST
Liver and intestinal toxicology testing both grew in the quarter ended September 30, 2026. VivoSim anticipates that the customer will make NAMkind™ testing part of its regular flow of ongoing...
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
November 16, 2026
New data on 10 compounds pulled due to unforeseen liver tox highlight how VivoSim’s models often easily catch clinical failure risk missed by animal models, using a complex approach that leverages...
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Labs and Chemveda Move Human-Tissue Testing Earlier in AI Drug Development
November 13, 2026
Via
AB Newswire
Topics
Artificial Intelligence
A Billionaire Investor Links Cancer Treatment and Wireless Technology as AI Pharmaceutical Testing Gains Ground
November 11, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
November 10, 2026
Company to feature two scientific poster presentations highlighting that its multiparametric approach delivers superior predictive power for both its DILI risk stratification and gastrointestinal...
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Post-Midterm Market Sectors and Companies Inside to Watch
November 05, 2026
Via
AB Newswire
3 Stocks Under $1: INO, VIVS, FNUC in Focus for November
November 03, 2026
Via
AB Newswire
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
November 03, 2026
Collaboration closes the loop between AI drug design and human biology: Chemveda designs and makes the molecules, VivoSim’s NAMkind™ 3D human liver and intestine models show which ones are safe to...
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
October 21, 2026
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials
From
VivoSim Labs, Inc.
Via
GlobeNewswire
5 Biotech Stocks’ TCRT, IGC, PDSB, PFAI, Acquisition, Alzheimer’s, Cardio and Cancer Research Milestones
October 13, 2026
Via
AB Newswire
Topics
Artificial Intelligence
4 Low-Priced Listed Stocks: VIVS, IGC, RIME, TOPP, With Catalysts to Watch
October 07, 2026
Via
AB Newswire
Topics
Animal Testing
Artificial Intelligence
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
October 07, 2026
As the FDA opens the door to non-animal safety testing, VivoSim's human-relevant models are already helping lower drug costs
From
VivoSim Labs, Inc.
Via
GlobeNewswire
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via
AB Newswire
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
September 28, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
September 28, 2026
Via
AB Newswire
Greenland Stocks in Focus: GLND, GRML, CRML Lead the Watchlist More Names Inside
September 21, 2026
Via
AB Newswire
Topics
Government
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem
September 21, 2026
Via
AB Newswire
Topics
Animal Testing
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
September 17, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Energy
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
September 16, 2026
New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
September 14, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
September 10, 2026
Via
AB Newswire
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
September 02, 2026
Via
AB Newswire
Microcaps GPRO, FLYE, HKPD, VIVS to Watch Now
September 01, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Supply Chain
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
September 01, 2026
New cross-species capability is designed to help pharma distinguish rat-specific liver toxicity from risks that may translate to humans
From
VivoSim Labs, Inc.
Via
GlobeNewswire
IGC Pharma (NYSE: IGC) Target Raised on Alzheimer’s 2027 Outlook
September 01, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human Toxicology
August 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks Now
August 26, 2026
Via
AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM Momentum
August 25, 2026
Via
AB Newswire
Topics
Animal Testing
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum
August 17, 2026
Via
AB Newswire
Topics
Animal Testing
Artificial Intelligence
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit